Mind Medicine (MindMed) Inc MNMD

Alternate Symbol(s): N.MMED.WS | N.MMED | N.MMED.WA | N.MMED.WR

Healthcare

Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing products to treat brain health disorders. It is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM-120 and MM-402, the Company's product candidates. MM120, is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that it is developing for the treatment of generalized anxiety disorder (GAD). MM-120 is also being studied in a subperceptual repeat administration dosing regimen for the treatment of attention deficit hyperactivity disorder (ADHD). MM-402, also referred to as R(-)-MDMA, is the Company's form of the R-enantiomer of 3,4-methylenedioxymethampheta (MDMA), which the Company is developing for the treatment of autism spectrum disorder (ASD).

NDAQ:MNMD - Post by User

Mind Medicine (MindMed) Inc

Bullboard Posts

Comment by grumpymonkey007on May 31, 2011 1:57pm

298 Views

Post# 18650810

RE: RE: RE:Brigus Gold: Investors Are Missing Its

You're faith in management is admirable.

to me it is more like New Guinea Gold:
- claim to be in production (June 2009) without ever hitting commercial levels
- late on filings
- coincidental positive and negative news releases within days
- repeated dilution even with what's reported to be a strong cash position
- repeated issuing of options to insiders without any proportional progress for common shareholders
- smoke and mirrors terminology such as the present hedge that eliminates all hedging

Apollo was supposedly at commercial production levels two years ago, so why aren't we rolling in the 4-bagger ROI?

Bullboard Posts

Victoria Gold: No cyanide detected downstream since mine incident